Scholarlink

<p>To meet the growing need for new therapies for major depressive disorder (MDD) and treatment-resistant depression (TRD), there has been renewed interest in the potential antidepressant activity of classic psychedelics, such as psilocybin and <i>N</i>,<i>N</i>-dimethyltryptamine. In several randomized controlled trials, psilocybin with adjunctive psychotherapy reduced the symptoms of TRD and MDD and was generally well tolerated, although longer-term data are lacking. The design of trials with psychoactive compounds requires optimisation to overcome the challenges of functional unblinding and expectancy; changing global perspectives and legislation may further support and improve investigation of classic psychedelics for the treatment of depressive disorders.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Classic psychedelics may treat depressive disorders, but more evidence and legislative changes are required

  • 期刊论文

  • 发表日期：

    2025年11月5日

查看全文
  • Aisling McGuigan

摘要

To meet the growing need for new therapies for major depressive disorder (MDD) and treatment-resistant depression (TRD), there has been renewed interest in the potential antidepressant activity of classic psychedelics, such as psilocybin and N,N-dimethyltryptamine. In several randomized controlled trials, psilocybin with adjunctive psychotherapy reduced the symptoms of TRD and MDD and was generally well tolerated, although longer-term data are lacking. The design of trials with psychoactive compounds requires optimisation to overcome the challenges of functional unblinding and expectancy; changing global perspectives and legislation may further support and improve investigation of classic psychedelics for the treatment of depressive disorders.